![Maria Siemionow](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Maria Siemionow
Oprichter bij
Dystrogen Therapeutics Corp.
Profiel
Maria Siemionow founded Tolera Therapeutics, Inc. in 2007, where she worked as Chief Science Technology Officer and Dystrogen Therapeutics Corp.
in 2017, where she is working as Chief Scientific Officer from 2017.
Actieve functies van Maria Siemionow
| Bedrijven | Functie | Begin |
|---|---|---|
Dystrogen Therapeutics Corp.
 Dystrogen Therapeutics Corp. Packaged SoftwareTechnology Services Develops platform for personalized therapies for rare genetic diseases | Oprichter | 01-01-2017 |
Eerdere bekende functies van Maria Siemionow
| Bedrijven | Functie | Einde |
|---|---|---|
Tolera Therapeutics, Inc.
 Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel therapies and technologies for immune modulation | Oprichter | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
3
Eerstegraads connecties
2
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Tolera Therapeutics, Inc.
Tolera Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Develops novel therapies and technologies for immune modulation | Commercial Services |
Dystrogen Therapeutics Corp.
Dystrogen Therapeutics Corp. Packaged SoftwareTechnology Services Develops platform for personalized therapies for rare genetic diseases | Technology Services |
